Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents
The introduction into clinical practice of immune checkpoint inhibitors that block cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death ligand-1 (PD-L1), has improved the prognosis of patients with malignant neoplasms of diff erent lo...
Bewaard in:
| Hoofdauteurs: | , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Russo |
| Gepubliceerd in: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2020-03-01
|
| Reeks: | Безопасность и риск фармакотерапии |
| Onderwerpen: | |
| Online toegang: | https://www.risksafety.ru/jour/article/view/168 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|